Health Condition 1: B359- Dermatophytosis, unspecified
Conditions
Interventions
Intervention1: Itraconazole (innovator) brand: Group A will recieved capsule itraconazole 100 mg BD(innovator)for 4 weeks
Control Intervention1: Itraconazole (multinational): Group B will recieved ca
Sponsors
Post graduate institute of medical education and research Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: All patients above the age of 18 years diagnosed clinically to have chronic dermatophytosis(excluding nail and scalp infections)
Exclusion criteria
Exclusion criteria: Pregnant and lactating mothers, patients on immunosuppressive drugs,patients with hepatitis b and c, hepatic and renal diseases with abnormal laboratories values, patient taking any drug interacting with itraconazole, per treatment with oral itraconazole and topical antifungal within 4 week and 2 week respectively,who unwilling to give written consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of plasma itraconazole level of three different brands(innovator,multinational,domestic) to estimate the target concentrations for therapeutic efficacy of itraconazole in chronic dermatophytosisTimepoint: Measurement of plasma itraconazole level of three different brands(innovator,multinational,domestic) to estimate the target concentrations for therapeutic efficacy of itraconazole in chronic dermatophytosis at 2 weeks and 4weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To observe any correlation between serum cortisol and clinical response to treatmentTimepoint: Cortisol measured in microgram per desiliter at base line clinical response will observe at 2 weeks, 4 weeks and 8 weeks | — |
Countries
India
Contacts
Public ContactDr Sunil dogra
Post graduate institute of medical education and research Chandigarh
Outcome results
None listed